Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Immuno-Oncology, Immunotherapy
Primmune Therapeutics, Inc.

Organization & Developments: Primmune Therapeutics

Parents

*Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.
2024: DTRA_Primmune Therapeutics Inc awarded a $22,480,552 contract HDTRA1-24-C-0014 for "Oral broad spectrum antiviral TLR7 agonist for treatment of Lassa Fever". This effort will support the Defense Threat Reduction Agency (DTRA) goal of providing counter weapons of mass destruction capabilities to meet current threats and challenges specifically through the development of a timely and effective biological defense solution for Lassa virus infection.
This award is the result of a competitive acquisition against the Broad Agency Announcement (BAA) HDTRA1-17-S-0002. SAM.gov was used to solicit proposals and 10 proposals were received. DTRA, DoDAAC HDTRA1, Fort Belvoir, Virginia, is the contracting activity.